Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Meneldor is a Netherlands-based investment organization that targets early-stage biotech and pharmaceutical companies. Founded to enable investors to collaborate with specialists in this complex sector, it conducts thorough assessments of potential portfolio companies. The firm focuses on projects in preclinical, Phase I, or Phase II stages, with a current portfolio of five companies.
Meneldor primarily invests in early-stage biotech and pharmaceutical companies developing new biological or chemical molecular entities. The firm targets projects that address significant unmet medical needs and possess strong intellectual property, particularly those with clear clinical endpoints. Investment stages include pre-seed, seed, and seed+ (extension), primarily within Western Europe.
Meneldor's notable portfolio companies include: Xenikos B.V., developing a drug therapy for acute Graft vs Host disease; Atriva Therapeutics GmbH, focused on novel antiviral drugs for respiratory infections; The Aptamer Group Ltd, specializing in nucleic acid aptamers; LightOx Ltd, creating fluorescent drugs for targeted cell destruction; and Tagworks Pharmaceuticals B.V., working on innovative cancer therapies.
To pitch Meneldor, email your deck to info@meneldor.nl.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.